洛铂联合绿脓杆菌制剂治疗恶性胸腔积液的临床观察

摘要

目的：观察洛铂联合绿脓杆菌制剂治疗恶性胸腔积液的临床效果。方法：将62例恶性胸腔积液患者引流排净积液后，32例患者注入洛铂和绿脓杆菌制剂（A 组）；30例患者注入顺铂和白介素－2（B 组），观察疗效、不良反应。结果：A 组32例患者中，CR 19例，SD 11例，有效率为93．8％；B 组30例患者中，CR 10例， SD 12例，有效率73．3％，两者差异有统计学意义（P ＝0．029）。在 A 组32例患者中，生活质量改善者29例（90．6％）；B 组30例患者中生活质量改善者16例（53．3％），两者差异有统计学意义（P ＝0．001）。A 组有效率和生活质量改善率显著优于 B 组。两组不良反应主要以Ⅰ、Ⅱ度恶心、呕吐，疲乏为主，不良反应两组比较差异均无统计学意义（P ＞0．05）。结论：洛铂联合绿脓杆菌制剂治疗恶性胸腔积液安全有效，不良反应轻微，值得临床应用和推广。%Objective:To observe the clinical efficacy of lobaplatin combined with PA -MSHA in the treatment of malignant hydrothorax.Methods:Lobaplatin combined with PA -MSHA was applied in 32 patients with malignant hy-drothorax(group A),30 patients with malignant hydrothorax treated by cisplatin and interleukin -2(group B).Re-sults:Following a maxnium release of hydrothorax,among 32 cases(group A),19 cases achieved CR,11 cases SD,ob-jective efficiency rate was 93.8%.In the group B,10 cases achieved CR,12 cases SD,objective efficiency rate was 73.3%,there was significant differences between two groups (P =0.029).Among 32 cases(group A),29 cases of patients were found to improve their quality of life(90.6%).Among 30 cases(group B),16 patients were found to improve their quality of life(53.3%),there was significant differences of two groups (P =0.001).Group A had a significantly better response rate and QOL improvement rate than group B.In two groups,the occurrence rates of grade I,II toxicities mainly including nausea,vomiting and fatigue,there was no significant differences(P >0.05).Conclu-sion:Lobaplatin combined with PA -MSHA can control the malignant hydrothorax,clinical safety is better,it is wor-thy of clinical generalization.